Current Report Filing (8-k)
December 19 2022 - 4:27PM
Edgar (US Regulatory)
0001622879
false
0001622879
2022-12-15
2022-12-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 15, 2022
Medicine Man
Technologies, Inc.
(Exact Name of Registrant as
Specified in Its Charter)
Nevada |
000-55450 |
46-5289499 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
4880 Havana Street, Suite 201
Denver, Colorado |
|
80239 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
|
|
(303) 371-0387 |
(Registrant’s Telephone Number, Including Area Code) |
|
|
|
Not Applicable |
(Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title of Each Class |
|
Trading Symbol(s) |
|
Name of Each Exchange On Which
Registered |
Not applicable |
|
Not applicable |
|
Not applicable |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 5.07 Submission of Matters to a Vote of Security Holders.
On December 15, 2022, Medicine Man Technologies,
Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”). The matters voted upon
and the results of the vote are set forth below.
Proposal 1: Election of Directors.
The Company’s stockholders elected all
nominees named in the proxy statement for the Annual Meeting to the Company’s board of directors, each to serve as a Class A director
for a two-year term expiring at the Company’s annual meeting of stockholders to be held in 2024 and until his successor is elected
and qualified, or until his earlier death, resignation or removal, with the following vote:
| |
For | |
Against | |
Abstain | |
Broker non-votes |
Jonathan Berger | |
73,965,825 | |
231,606 | |
101,815 | |
11,622,419 |
Jeffrey Cozad | |
73,952,907 | |
234,616 | |
111,723 | |
11,622,419 |
Jeffrey Garwood | |
65,837,316 | |
165,161 | |
8,296,769 | |
11,622,419 |
Paul Montalbano | |
63,049,822 | |
11,010,728 | |
238,696 | |
11,622,419 |
Salim Wahdan | |
74,052,154 | |
140,215 | |
106,877 | |
11,622,419 |
Proposal 2: Ratification of Appointment
of Independent Public Accountant.
The Company’s stockholders ratified
the appointment of BF Borgers, CPA P.C. as the Company’s independent public accountant for the fiscal year ending December 31, 2022,
with the following vote:
For | |
Against | |
Abstain | |
Broker non-votes |
85,706,266 | |
114,525 | |
100,874 | |
0 |
Item 7.01 Regulation FD Disclosure.
On December 19, 2022,
the Company issued a press release announcing the closing of the acquisition of substantially all of the operating assets of two retail
dispensaries owned by Lightshade Labs LLC (“Lightshade”). A copy of the press release is furnished as Exhibit 99.1 to this
Current Report on Form 8-K and incorporated herein by reference.
The information under
Item 7.01 of this Current Report on Form 8-K and the press release attached as Exhibit 99.1 are being furnished by the Company pursuant
to Item 7.01. In accordance with General Instruction B.2 of Form 8-K, the information under Item 7.01 of this Current Report on Form 8-K,
including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934,
as amended, or otherwise subject to the liability of that section. In addition, this information shall not be deemed incorporated by reference
into any of the Company’s filings with the Securities and Exchange Commission, except as shall be expressly set forth by specific
reference in any such filing.
Item 8.01 Other Events.
On
December 15, 2022, Double Brow, LLC (“Buyer”), a wholly-owned subsidiary of the Company, acquired substantially all of the
operating assets associated with two Lightshade retail dispensaries and assumed specified obligations of Lightshade pursuant to the terms
of two Asset Purchase Agreements, dated September 9, 2022 (the “Purchase Agreements”), among Buyer, the Company, Lightshade,
Thomas Van Alsburg, an individual, Steve Brooks, an individual, and John Fritzel, an individual
(together with Mr. Alsburg and Mr. Brooks, the “Equityholders”). Pursuant to the Purchase Agreements, Buyer acquired
all of Lightshade’s assets related to its retail cannabis stores located in Denver, Colorado and Aurora, Colorado (other than assets
expressly excluded from the acquisition under the Purchase Agreements), which included two retail dispensary stores, the associated leases,
and assumed certain liabilities for contracts acquired under the Purchase Agreement (collectively, the “Acquisition”).
After purchase price
adjustments for transaction and related expenses, the aggregate consideration for the Acquisition was approximately $2.75 million, all
of which was paid in cash. The purchase price is subject to post-closing reduction if any of the actual marijuana inventory or cash at
closing is less than certain targets stated in the Purchase Agreement. The Company deposited $300,000 of the purchase price in escrow
as collateral for potential claims for indemnification from Lightshade under the Purchase Agreements. Any of the purchase price placed
in escrow and not used to satisfy indemnification claims will be released on December 15, 2023, twelve months following the closing date
of the Acquisition. The Company funded the Acquisition from cash on hand.
The Company previously reported the terms
of the Purchase Agreements and the transactions contemplated thereby in Item 8.01 of the Company’s Current Report on Form 8-K filed
on September 15, 2022. The preceding description of the Acquisition and the Purchase Agreements does not purport to be complete and is
qualified in its entirety by reference to the copies of the Purchase Agreements attached hereto as Exhibit 10.1 and Exhibit 10.2, which
are incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
Description |
10.1 |
Asset Purchase Agreement, dated September 9, 2022, by and among Medicine Man Technologies, Inc., Double Brow, LLC, Lightshade Labs LLC, Thomas Van Alsburg, Steve Brooks, and John Fritzel (Incorporated by reference to Exhibit 2.1 to Medicine Man Technologies, Inc.’s Quarterly Report on Form 10-Q filed November 10, 2022 (Commission File No. 00055450)) |
10.2 |
Asset Purchase Agreement, dated September 9, 2022, by and among Medicine Man Technologies, Inc., Double Brow, LLC, Lightshade Labs LLC, Thomas Van Alsburg, Steve Brooks, and John Fritzel (Incorporated by reference to Exhibit 2.2 to Medicine Man Technologies, Inc.’s Quarterly Report on Form 10-Q filed November 10, 2022 (Commission File No. 00055450)) |
99.1 |
Press Release, dated December 19, 2022 |
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MEDICINE MAN TECHNOLOGIES, INC. |
|
|
|
By: |
/s/ Daniel R. Pabon |
Date: December 19, 2022 |
|
Daniel R. Pabon General Counsel |
Medicine Man Technologies (QX) (USOTC:SHWZ)
Historical Stock Chart
From Apr 2024 to May 2024
Medicine Man Technologies (QX) (USOTC:SHWZ)
Historical Stock Chart
From May 2023 to May 2024